Results in rheumatology of the EPAS-FAMEB study: Post-authorization study to evaluate the safety of biological DMARDs

被引：0
|
作者：
Hidalgo Rios, Samuel [1 ]
Ramos Pardillo, Natalia [1 ]
Torello Iserte, Jaime [1 ]
Jimenez Martin, Carmen Maria [1 ]
Maiquez Asuero, Pilar [1 ]
Aguilera Cros, Pura Clara [2 ]
机构：
[1] Hosp Univ Virgen Rocio, Farmacol Clin, Seville, Spain
[2] Hosp Univ Virgen Rocio, Cirugia Ortoped Traumatol & Reumatol, Seville, Spain
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2022年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
29
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [1] Post-Authorization Safety Study of the Utilization of Apixaban in Sweden
    Linder, Marie
    Schachterle, Stephen E.
    Ataher, Quazi
    Andersen, Morten
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 567 - 567
  • [2] Safety of Alemtuzumab in Patients with Multiple Sclerosis: Interim Results of a Post-Authorization Safety Study (PASS)
    Montalban, X.
    Van Wijmeersch, B.
    Gobbi, C.
    Robertson, N.
    Klotz, L.
    Achiron, A.
    Lee, A.
    Eichau, S.
    Vecsei, L.
    Benzerdjeb, H.
    Rodrigues, A.
    Jurgensen, S.
    Chirieac, M.
    Comi, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 288 - 288
  • [3] Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany
    Hoechstetter, Manuela A.
    Knauf, Wolfgang
    Dambacher, Silvia
    Hucke, Nike
    Hoehne, Kristin
    van Troostenburg, Anna
    Ramroth, Heribert
    Abenhardt, Wolfgang
    Rummel, Mathias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : E777 - E787
  • [4] Design of a Multinational Post-Authorization Safety Study (PASS) of Crizotinib
    Ehrenstein, Vera
    Huang, Kui
    Kahlert, Johnny
    Bahmanyar, Shahram
    Karlsson, Par
    Lofling, Lukas
    Bezemer, Irene D.
    Kuiper, Josine G.
    Nunes, Anthony P.
    Enger, Cheryl
    Hoti, Fabian
    Juuti, Rosa
    Korhonen, Pasi
    Mo, Jingping P.
    Schachterle, Stephen
    Sorensen, Henrik T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 311 - 312
  • [5] Agomelatine post-authorization safety studies program: Comprehensive results
    Jacquot, Emmanuelle
    Olivier, Valerie
    Percheron, Christele
    Mazens, Fanny
    Deltour, Nicolas
    Perez-Gutthann, Susana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 246 - 246
  • [6] Challenges of post-authorization safety studies: Lessons learned and results of a French study of fentanyl buccal tablet
    Gavrielov-Yusim, Natalie
    Bidollari, Ilda
    Kaplan, Sigal
    Bartov, Netta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (05) : 457 - 463
  • [7] Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study
    Estilo, Alvin
    McCormick, Linda
    Rahman, Mirza
    ADVANCES IN THERAPY, 2021, 38 (12) : 5721 - 5736
  • [8] Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study
    Alvin Estilo
    Linda McCormick
    Mirza Rahman
    Advances in Therapy, 2021, 38 : 5721 - 5736
  • [9] fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study
    Ciznar, Peter
    Roderick, Marion
    Schneiderova, Helen
    Jesenak, Milos
    Krivan, Gergely
    Brodszki, Nicholas
    Jolles, Stephen
    Atisso, Charles
    Fielhauer, Katharina
    Saeed-Khawaja, Shumyla
    McCoy, Barbara
    Yel, Leman
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2024, 20 (01):
  • [10] CARDIOVASCULAR SAFETY OF USTEKINUMAB VERSUS ETANERCEPT IN PSORIASIS: RESULTS FROM AN OBSERVATIONAL POST-AUTHORIZATION SAFETY STUDY BASED ON SWEDISH NATIONAL REGISTERS
    Banefelt, Jonas
    Skroeder, Helena
    Azzabi, Ahlem
    Sheahan, Anna
    Suruki, Robert
    Geldhof, Anja
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
12345